Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis

Launched by BEIJING CHILDREN'S HOSPITAL · Aug 8, 2018

Keywords

ClinConnect Summary

This clinical trial is studying how anti-tuberculosis drugs work in children with tuberculosis (TB). Researchers believe that the way these drugs behave in children's bodies is different from adults. They will collect blood samples from children receiving TB treatment to measure how much of the medication is in their system. By analyzing this data, they hope to understand how well the drugs are working and whether they cause any side effects. This information will help improve TB treatment in children and lay the groundwork for future research.

To participate in this study, children aged 0 to 18 who are currently receiving anti-tuberculosis therapy can be included. Parents or guardians must provide consent for their child to join the trial. However, children who are allergic to these medications, or those who cannot provide complete medical records, will not be eligible. If chosen to participate, families can expect to provide blood samples for testing, and the study will help contribute to better treatment options for children with TB in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Children (0-18 years old) with anti-tuberculosis therapy against TB.
• • The anti-tuberculsis therapy includes drugs commonly used in children infectious diseases
• • Informed consent signed by the parents and/or guardians.
• Exclusion Criteria:
• • Anti-tuberculosis drugs aren't involved in the therapies of children.
• • It is unable to provide complete medical records or the current condition cannot accept the study process.
• • Patients are allergic to anti-tuberculsis drugs.
• • Parents and/or guardians do not agree to participate in this study.